{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T19:40:26Z","timestamp":1741203626376,"version":"3.38.0"},"publisher-location":"Basel","reference-count":73,"publisher":"Birkh\u00e4user Basel","isbn-type":[{"type":"print","value":"9783034895477"},{"type":"electronic","value":"9783034883931"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000]]},"DOI":"10.1007\/978-3-0348-8393-1_8","type":"book-chapter","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T06:03:24Z","timestamp":1306044204000},"page":"123-139","source":"Crossref","is-referenced-by-count":0,"title":["Molecular approaches to receptors as targets for drug discovery"],"prefix":"10.1007","author":[{"given":"Dean B.","family":"Evans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Traxler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Garc\u00eda-Echeverr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0960-894X(98)00701-X","volume":"9","author":"J Schoepfer","year":"1999","unstructured":"Schoepfer J, Fretz H, Gay B, Furet P, Garc\u00eda-Echeverr\u00eda C, End N, Caravatti G (1999) Highly potent inhibitors of the Grb2-SH2 domain.Bioorg Med Chem Lett9: 221\u2013226","journal-title":"Bioorg Med Chem Lett"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1021\/jm970856n","volume":"41","author":"C Garc\u00eda-Echeverr\u00eda","year":"1998","unstructured":"Garc\u00eda-Echeverr\u00eda C, Furet P, Gay B, Fretz H, Rahuel J, Schoepfer J, Caravatti G (1998) Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-ZTyr(PO3H2)-X`1-Asn-NH2.J Med Chem41: 1741\u20131744","journal-title":"J Med Chem"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/jm980159a","volume":"41","author":"P Furet","year":"1998","unstructured":"Furet P, Gay B, Caravatti G, Garc\u00eda-Echeverr\u00eda C, Rahuel J, Schoepfer J, Fretz H (1998) Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.J Med Chem41: 3442\u20133449","journal-title":"J Med Chem"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1006\/jmbi.1998.1790","volume":"279","author":"J Rahuel","year":"1998","unstructured":"Rahuel J, Garc\u00eda-Echeverr\u00eda C, Furet P, Strauss A, Caravatti G, Fretz H, Schoepfer J, Gay B (1998) Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.J Mol Biol279: 1013\u20131022","journal-title":"J Mol Biol"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1016\/S0960-894X(98)00513-7","volume":"8","author":"J Schoepfer","year":"1998","unstructured":"Schoepfer J, Gay B, Caravatti G, Garc\u00eda-Echeverr\u00eda C, Fretz H, Rahuel J, Furet P (1998) Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.Bioorg Med Chem Lett8: 2865\u20132870","journal-title":"Bioorg Med Chem Lett"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1021\/jm9702185","volume":"40","author":"P Furet","year":"1997","unstructured":"Furet P, Gay B, Garc\u00eda-Echeverr\u00eda C, Rahuel J, Fretz H, Schoepfer J, Caravatti G (1997) Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.J Med Chem40: 3551\u20133556","journal-title":"J Med Chem"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/stem.160413","volume":"16","author":"JE Ross","year":"1998","unstructured":"Ross JE, Fletcher J (1998) The HER-2\/neu onogene in breast cancer: prognostic factor, predictive factor, and target for therapy.Stem Cells16: 413\u2013428","journal-title":"Stem Cells"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1517\/13543784.7.4.553","volume":"7","author":"LM Strawn","year":"1998","unstructured":"Strawn LM, Shawver LK (1998) Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Expert Opin Invest Drugs7: 553\u2013573","journal-title":"Expert Opin Invest Drugs"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1517\/14728214.3.1.279","volume":"3","author":"AJ Bridges","year":"1998","unstructured":"Bridges AJ (1998) Current progress towards the development of tyrosine kinase inhibitors as anticancer agents.Emerg Drugs3: 279\u2013292","journal-title":"Emerg Drugs"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1517\/13543784.6.6.771","volume":"6","author":"F Lavelle","year":"1997","unstructured":"Lavelle F (1997) American Association forCancer Res1997: progress and new hope in the fight against cancer, April 12\u201316, 1997, San Diego, California.Expert Opin Invest Drugs6: 12\u201316","journal-title":"Expert Opin Invest Drugs"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0968-0004(97)01131-6","volume":"22","author":"CM Smith","year":"1997","unstructured":"Smith CM, Shindayalov IN, Veretnik S, Gribskov M, Taylor SS, Ten Eyck LF, Bourne PE (1997) The protein kinase resource.Trends Biochem Sci22: 444\u2013446","journal-title":"Trends Biochem Sci"},{"volume-title":"The protein kinase facts book: protein-tyrosine kinases","year":"1995","key":"8_CR12","unstructured":"Hardie G, Hanks S (eds) (1995)The protein kinase facts book: protein-tyrosine kinases.Academic Press, London"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/0076-6879(91)00126-H","volume":"200","author":"S Hanks","year":"1991","unstructured":"Hanks S, Quinn AM (1991) Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members.Meth Enzymol200: 38\u201362","journal-title":"Meth Enzymol"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/A:1008209720526","volume":"12","author":"BR Voldborg","year":"1997","unstructured":"Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGF-R) and EGF-R mutations, function and possible role in clinical trials.Ann Oncol12: 1197\u20131206","journal-title":"Ann Oncol"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptor.FASEB J13: 9\u201322","journal-title":"FASEB J"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0969-2126(99)80042-2","volume":"7","author":"MA McTigue","year":"1999","unstructured":"McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, Gehring MR, Mroczkowski B, Kan C-C, Villafranca JE et al (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.Structure7: 319\u2013330","journal-title":"Structure"},{"key":"8_CR17","first-page":"D165\u2014D177","volume":"4","author":"P Klint","year":"1999","unstructured":"Klint P, Claesson-Welsh L (1999) Signal transduction by fibroblast growth factor receptors.Front Biosci4: D165\u2014D177","journal-title":"FrontBiosci"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1093\/emboj\/17.20.5896","volume":"17","author":"M Mohammadi","year":"1998","unstructured":"Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.EMBO J17: 5896\u20135904","journal-title":"EMBO J"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1126\/science.276.5314.955","volume":"276","author":"M Mohammadi","year":"1997","unstructured":"Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J (1997) Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.Science276: 955\u2013960","journal-title":"Science"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(00)80131-2","volume":"86","author":"M Mohammadi","year":"1996","unstructured":"Mohammadi M, Schlessinger J, Hubbard SR (1996) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.Cell86: 577\u2013587","journal-title":"Cell"},{"key":"8_CR21","first-page":"F79\u2014F113","volume":"1378","author":"CH Heldin","year":"1998","unstructured":"Heldin CH, \u00d6stman A, R\u00f6nnstrand L (1998) Signal transduction via platelet-derived growth factor receptors.Biochim Biophys Acta1378: F79\u2014F113","journal-title":"Biochim Biophys Acta"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1126\/science.1659742","volume":"254","author":"AA Aaronson","year":"1991","unstructured":"Aaronson AA (1991) Growth factors and cancer.Science254: 1146\u20131153","journal-title":"Science"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/0020-711X(94)90091-4","volume":"26","author":"JA Boutin","year":"1994","unstructured":"Boutin JA (1994) Tyrosine protein kinase inhibition and cancer.Int J Biochem26: 1203\u20131226","journal-title":"Int J Biochem"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1432-1033.1994.tb20020.x","volume":"226","author":"A Levitzki","year":"1994","unstructured":"Levitzki A (1994) Signal-transduction therapy.Eur J Biochem226: 1\u201313","journal-title":"Eur J Biochem"},{"key":"8_CR25","first-page":"131","volume":"1","author":"G McMahon","year":"1998","unstructured":"McMahon G, Sun L, Liang C, Tang C (1998) Protein kinase inhibitors: structural determinants for target specificity.Curr Opin Drug Discover Develop1: 131\u2013146","journal-title":"Curr Opin Drug Discover Develop"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/13543776.8.12.1599","volume":"8","author":"P Traxler","year":"1998","unstructured":"Traxler P (1998) Tyrosine kinase inhibitors in cancer treatment (part II).Expert Opin Ther Patents8: 1599\u20131625","journal-title":"Expert Opin Ther Patents"},{"key":"8_CR27","first-page":"55","volume":"76","author":"HD Hollis Showalter","year":"1997","unstructured":"Hollis Showalter HD, Kraker AJ (1997) Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and src family tyrosine kinases.Pharmacol Ther76: 55\u201371","journal-title":"PharmacolTher"},{"key":"8_CR28","first-page":"4838","volume":"57","author":"JD Moyer","year":"1997","unstructured":"Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinaseCancer Res57: 4838\u20134848","journal-title":"Cancer Res"},{"key":"8_CR29","first-page":"6333","volume":"38","author":"JR Woodburn","year":"1997","unstructured":"Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L, Henthorn LR (1997) ZD 1839, an epidermal growth factor tyrosine kinase inhibitors selected for clinical development.Proc Amer Assoc Cancer Res38: 6333","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/jm970641d","volume":"41","author":"GW Rewcastle","year":"1998","unstructured":"Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT et al (1998) Tyrosine kinase inhibitors. 14. structure-activity relationships for methyl-amino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3, 4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.J Med Chem41: 742\u2013751","journal-title":"J Med Chem"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1021\/jm9508651","volume":"39","author":"GF Rewcastle","year":"1996","unstructured":"Rewcastle GF, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou HM, Fry DW, McMichael A, Denny WA (1996) Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.J Med Chem39: 1823\u20131835","journal-title":"J Med Chem"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1021\/jm960879m","volume":"40","author":"GF Rewcastle","year":"1997","unstructured":"Rewcastle GF, Bridges AJ, Fry DW, Rubin JR, Denny WA (1997) Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5, 4d]pyrimidies designed as inhibitors of the epidermal growth factor receptor.J Med Chem40: 1820\u20131826","journal-title":"J Med Chem"},{"key":"8_CR33","first-page":"813","volume":"1","author":"E Buchdunger","year":"1995","unstructured":"Buchdunger E, Trinks U, Mett H, Regenass U, Muller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P et al (1995) 4,5-Bis(4-fluoroanilino)phthalimide: a selective inhibitor of the EGF receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res 1: 813\u2013821","journal-title":"Clin Cancer Res"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1073\/pnas.91.6.2334","volume":"91","author":"E Buchdunger","year":"1994","unstructured":"Buchdunger E, Trinks U, Mett H, Regenass U, Muller M, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB (1994) 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potentin vivoantitumor activity.Proc Natl Acad Sci USA91: 2334\u20132338","journal-title":"Proc Natl Acad Sci USA"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1021\/jm970124v","volume":"40","author":"P Traxler","year":"1997","unstructured":"Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3, 4-d]pyrimidines.J Med Chem40: 3601\u20133616","journal-title":"J Med Chem"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1021\/jm960118j","volume":"39","author":"PM Traxler","year":"1996","unstructured":"Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N (1996) 4(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGFreceptor protein tyrosine kinase.J Med Chem39: 2285\u20132292","journal-title":"J Med Chem"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0960-894X(96)00601-4","volume":"7","author":"J Zimmermann","year":"1997","unstructured":"Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB (1997) Potent and selective inhibitors of the ABL-kinase: phenylaminopyridine (PAP) derivatives.Bioorg Med Chem Lett7: 187\u2013192","journal-title":"Bioorg Med Chem Lett"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ardp.19963290707","volume":"329","author":"J Zimmermann","year":"1996","unstructured":"Zimmermann J, Caravatti G, Mett H, Meyer T, Mueller M, Lydon NB, Fabbro D (1996) Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).Arch Pharm (Weinheim Ger.)329: 371\u2013376","journal-title":"Arch Pharm (Weinheim, Ger.)"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/S0960-894X(97)10110-X","volume":"7","author":"MR Barvian","year":"1997","unstructured":"Barvian MR, Panek RL, Lu GH, Kraker AJ, Amar A, Hard BG, Hamby JM, Showalter HDH (1997) 1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase.Bioorg Med Chem Lett7: 2903\u20132908","journal-title":"Bioorg Med Chem Lett"},{"key":"8_CR40","first-page":"99","volume":"59","author":"TAT Fong","year":"1999","unstructured":"Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W et al (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.Cancer Res59: 99\u2013106","journal-title":"Cancer Res"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/jm980123i","volume":"41","author":"L Sun","year":"1998","unstructured":"Sun L, Tran F, App H, Hirth P, McMahon G, Tang C (1998) Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular RTKs.J Med Chem41: 2588\u20132603","journal-title":"J Med Chem"},{"key":"8_CR42","first-page":"1887","volume":"4","author":"CA Dionne","year":"1998","unstructured":"Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff NT, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S et al (1998) Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).Clin Cancer Res4: 1887\u20131898","journal-title":"ClinCancer Res"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/BF00124317","volume":"9","author":"P Furet","year":"1995","unstructured":"Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U, Traxler P (1995) Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP52411.J Computer-Aided Molec Design9: 465\u2013472","journal-title":"J Computer-Aided Molec Design"},{"key":"8_CR44","first-page":"550","volume":"11","author":"S Trumpp-Kallmeyer","year":"1998","unstructured":"Trumpp-Kallmeyer S, Showalter HD (1998) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylan\u00fano)pyrazolo[3,4-dlpyrimidines.Chemtracts 11:550\u2013560","journal-title":"Chemtracts"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1021\/jm970634p","volume":"41","author":"S Trumpp-Kallmeyer","year":"1998","unstructured":"Trumpp-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showalter HDH (1998) Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.J Med Chem41: 1752\u20131763","journal-title":"J Med Chem"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1021\/jm980551o","volume":"42","author":"P Traxler","year":"1999","unstructured":"Traxler P, Green J, Mett H, S\u00e9quin U, Furet P (1999) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.JMed Chem42: 1018\u20131026","journal-title":"JMed Chem"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0163-7258(97)00052-1","volume":"77","author":"DS Lawrence","year":"1998","unstructured":"Lawrence DS, Niu J (1998) Protein kinase inhibitors: the tyrosine-specific protein kinases.Pharmacol Ther77: 81\u2013114","journal-title":"Pharmacol Ther"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/0196-9781(94)90057-4","volume":"15","author":"DW Fry","year":"1994","unstructured":"Fry DW, McMichael A, Singh J, Dobrusin EM, McNamara DJ (1994) Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-gamma 1.Peptides15: 951\u2013957","journal-title":"Peptides"},{"key":"8_CR49","doi-asserted-by":"crossref","first-page":"16 205","DOI":"10.1016\/S0021-9258(17)46208-9","volume":"265","author":"CJ Yuan","year":"1990","unstructured":"Yuan CJ, Jakes S, Elliott S, Graves DJ (1990) A rationale for the design of an inhibitor of tyrosyl kinase.J Biol Chem265: 16 205\u201316 209","journal-title":"J Biol Chem"},{"key":"8_CR50","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1016\/S0021-9258(18)83117-9","volume":"264","author":"SE Shoelson","year":"1989","unstructured":"Shoelson SE, White MF, Kahn CR (1989) Nonphosphorytable substrate analogs selectively block autophosphorylation and activation of the insulin receptor, epidermal growth factor receptor, and pp60v-src kinases.J Biol Chem264: 7831\u20137836","journal-title":"J Biol Chem"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7164\/antibiotics.39.170","volume":"39","author":"H Umezawa","year":"1986","unstructured":"Umezawa H, Imoto M, Sawa T, Issihiki K, Matsuda N, Uchida T, Finuma H, Hamada M, Takeuchi T (1986) Studies on a new epidermal growth factor kinase inhibitors, erbstatin, produce by MH435-hF3.J Antibiot39: 170\u2013173","journal-title":"J Antibiot"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.7164\/antibiotics.40.1471","volume":"40","author":"M Imoto","year":"1987","unstructured":"Imoto M, Umezawa K, Isshiki K, Kunimoto S, Sawa T, Takeuchi T, Umezawa H (1987) Kinetic studies of tyrosine kinase inhibition by erbstatin.J Antibiot40: 1471\u20131473","journal-title":"J Antibiot"},{"key":"8_CR53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0026-895X(25)10152-1","volume":"45","author":"I Posner","year":"1994","unstructured":"Posner I, Engel M, Gazit A, Levitzki A (1994) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.Mol Pharmacol45: 673\u2013683","journal-title":"Mol Pharmacol"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0165-6147(91)90538-4","volume":"12","author":"A Levitzki","year":"1991","unstructured":"Levitzki A, Gazit A (1991) Tyrphostins as molecular tools and potential antiproliferative drugs.Trends Pharmacol Sci12: 171\u2013174","journal-title":"Trends Pharmacol Sci"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzki","year":"1995","unstructured":"Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development.Science267: 1782\u20131788","journal-title":"Science"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/0006-2952(94)90280-1","volume":"48","author":"WK Agbotounou","year":"1994","unstructured":"Agbotounou WK, Mousset S, Piperno S, Pierre M, Jacquemin-Sablon A, Pierre J (1994) Activation of the mitogen-activated protein kinase cascade by tyrphostin.Biochem Pharmacol48: 505\u2013515","journal-title":"Biochem Pharmacol"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0014-5793(93)81308-M","volume":"316","author":"SW Young","year":"1993","unstructured":"Young SW, Poole RC, Hudson AT, Halestrap AP, Denton RM, Tavar\u00e9 JM (1993) Effects of tyrosine kinase inhibitors on protein kinase-independent systems.FEBS Lett316: 278\u2013282","journal-title":"FEBS Lett"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0968-0004(98)01241-9","volume":"23","author":"MJ Wishart","year":"1998","unstructured":"Wishart MJ, Dixon JE (1998) Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains.Trends Biochem Sci23: 301\u2013306","journal-title":"Trends Biochem Sci"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-80481-6_1","volume":"228","author":"BJ Mayer","year":"1998","unstructured":"Mayer BJ, Gupta R (1998) Functions of SH2 and SH3 domains.Curr Topic Microbiol Immunol228: 1\u201322","journal-title":"Curr Topic Microbiol Immunol"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0968-0004(00)89103-3","volume":"20","author":"SY Zhou","year":"1995","unstructured":"Zhou SY, Cantley LC (1995) Recognition and specificity in protein tyrosine kinase-mediated signalling.Trends Biochem Sci20: 470\u2013475","journal-title":"Trends Biochem Sci"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1128\/MCB.14.4.2777","volume":"14","author":"Z Songyang","year":"1994","unstructured":"Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T et al (1994) Specific motifs recognized by the SH2 domain of Csk, 3BP2, fps\/fes, Grb-2, HCP, SHC, syk, and Vay.Mol Cell Biol14: 2777\u20132785","journal-title":"Mol Cell Biol"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/0092-8674(93)90404-E","volume":"72","author":"Z Songyang","year":"1993","unstructured":"Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ et al (1993) SH2 domains recognize specific phosphopeptide sequences.Cell72: 767\u2013778","journal-title":"Cell"},{"key":"8_CR63","first-page":"16 500","volume":"28","author":"K M\u00fcller","year":"1996","unstructured":"M\u00fcller K, Gombert FO, Manning U, Grossm\u00fcller F, Graff P, Zaegel H, Zuber JF, Freuler F, Tschopp C, Baumann G (1996) Rapid identification of phosphopeptide ligands for SH2 domains.J Mol Biol28: 16 500\u201316 505","journal-title":"J Mol Biol"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1432-1033.1997.00633.x","volume":"246","author":"H Gram","year":"1997","unstructured":"Gram H, Schmitz R, Zuber JF, Baumann G (1997) Identification of phosphopeptide ligands for the Src-homology 2 (SH2) domain of Grb2 by phage display.Eur J Biochem246: 633\u2013637","journal-title":"Eur J Biochem"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P","volume":"47","author":"TK Sawyer","year":"1998","unstructured":"Sawyer TK (1998) Src homology-2 domains: structure, mechanisms, and drug discovery.Biopolymers (Peptide Science)47: 243\u2013261","journal-title":"Biopolymers (Peptide Science)"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1016\/S0040-4020(98)00192-6","volume":"54","author":"H Fretz","year":"1998","unstructured":"Fretz H (1998) O-(Carboxydifluoromethyl)-L-tyrosine: design and synthesis of a novel non phosphorous-containing phosphotyrosine isostere.Tetrahedron54: 4849\u20134858","journal-title":"Tetrahedron"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"8479","DOI":"10.1016\/0040-4039(96)01979-X","volume":"37","author":"H Fretz","year":"1996","unstructured":"Fretz H (1996) Solid phase synthesis of peptides containing novel L-phenylalanine substituted with vicinal tricarbonyl moieties.Tetrahedron Lett37: 8479\u20138482","journal-title":"Tetrahedron Lett"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"8475","DOI":"10.1016\/0040-4039(96)01978-8","volume":"37","author":"H Fretz","year":"1996","unstructured":"Fretz H (1996) Synthesis of novel L-phenylalanine derivatives substituted with a keto ylide as stable precursor of a vicinal tricarbonyl moiety.Tetrahedron Lett37: 8475\u20138478","journal-title":"Tetrahedron Lett"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1021\/jm950621g","volume":"39","author":"TRJr Burke","year":"1996","unstructured":"Burke TR Jr, Ye B, Akamatsu M, Ford H, Yan X, Kole HK, Wolf G, Shoelson SE, Roller PP (1996) 4-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides.J Med Chem39: 1021\u20131027","journal-title":"J Med Chem"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1016\/0040-4039(95)00890-O","volume":"36","author":"B Ye","year":"1995","unstructured":"Ye B, Burke TR Jr (1995) L-O-(2-Malonyl)tyrosine (L-OMT), a new phosphotyrosyl mimic suitably protected for solid-phase synthesis of signal transduction inhibitory peptides.Tetrahedron Lett36: 4733\u20134736","journal-title":"Tetrahedron Lett"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1021\/jo00058a009","volume":"58","author":"TR Jr Burke","year":"1993","unstructured":"Burke TR Jr, Smyth MS, Nomizu M, Otaka A, Roller PR (1993) Preparation of fluoro-and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of 0-phosphotyrosine.J Org Chem58: 1336\u20131340","journal-title":"J Org Chem"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1016\/0040-4039(91)80753-S","volume":"32","author":"SE Shoelson","year":"1991","unstructured":"Shoelson SE, Chatterjee S, Chaudhuri M, Burke TR Jr (1991) Solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues with N\u00b0-Fmoc-(O,O-di-t-butyl)phosphono-pmethylphenylalanine.Tetrahedron Lett32: 6061\u20136064","journal-title":"Tetrahedron Lett"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1021\/jm980388x","volume":"42","author":"Z-J Yao","year":"1999","unstructured":"Yao Z-J, King CR, Cao T, Kelley J, Milne GWA, Voigt JH, Burke TR Jr (1999) Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.J Med Chem42: 25\u201335","journal-title":"J Med Chem"}],"container-title":["Experientia Supplementum","New Approaches to Drug Development"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-0348-8393-1_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T19:09:25Z","timestamp":1741201765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-0348-8393-1_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"ISBN":["9783034895477","9783034883931"],"references-count":73,"URL":"https:\/\/doi.org\/10.1007\/978-3-0348-8393-1_8","relation":{},"ISSN":["1023-294X"],"issn-type":[{"type":"print","value":"1023-294X"}],"subject":[],"published":{"date-parts":[[2000]]}}}